^
    9d
    Rad2Nivo: Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=39, Active, not recruiting, University of Utah | Trial completion date: Apr 2026 --> Dec 2026 | Trial primary completion date: Feb 2025 --> Apr 2026
    Trial completion date • Trial primary completion date • Tumor mutational burden
    |
    Opdivo (nivolumab) • Xofigo (radium Ra-223 dichloride)
    13d
    AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01) (clinicaltrials.gov)
    P3, N=670, Recruiting, AstraZeneca
    New P3 trial
    |
    FOLH1 positive
    |
    enzalutamide • abiraterone acetate • Nubeqa (darolutamide) • cabazitaxel • apalutamide • Xofigo (radium Ra-223 dichloride) • AiRuiEn (rezvilutamide) • FPI-2265 • prednisolone
    1m
    Preclinical Evaluation of Radium-223 and Immune Checkpoint Inhibitors Using an Immune-Competent Model of Prostate Cancer Bone Metastases. (PubMed, Precis Oncol)
    223RaCl2 localizes primarily to bone surfaces, limiting direct cytotoxic and immunomodulatory effects within the tumor microenvironment. While combination with ICIs did not improve efficacy, these findings provide a platform for studying spatial dose distribution and support future development of tumor-targeted alpha therapies to potentiate immunotherapy in mCRPC.
    Preclinical • Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CD4 (CD4 Molecule)
    |
    Xofigo (radium Ra-223 dichloride)
    1m
    Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy (clinicaltrials.gov)
    P1/2, N=90, Recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    Bavencio (avelumab) • peposertib (M3814) • Xofigo (radium Ra-223 dichloride)
    1m
    A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones (clinicaltrials.gov)
    P2, N=12, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: Nov 2027 --> Apr 2026 | Trial primary completion date: Nov 2027 --> Apr 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    Xofigo (radium Ra-223 dichloride)
    2ms
    Low-Count Quantitative SPECT for Men Treated With Radium-223 (clinicaltrials.gov)
    P=N/A, N=38, Not yet recruiting, Washington University School of Medicine | Trial completion date: Mar 2028 --> Jul 2028 | Initiation date: Mar 2026 --> Jul 2026 | Trial primary completion date: Dec 2027 --> Apr 2028
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    Xofigo (radium Ra-223 dichloride)
    2ms
    SHARP: Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer (clinicaltrials.gov)
    P2, N=25, Active, not recruiting, City of Hope Medical Center | Trial completion date: Feb 2026 --> Jan 2027
    Trial completion date
    |
    Eligard (leuprolide acetate) • goserelin acetate • Firmagon (degarelix) • Xofigo (radium Ra-223 dichloride) • Viadur (leuprorelin implant)
    2ms
    DUET study: DUET-study: A FEASIBILITY STUDY OF 177LU-PSMA RADIOLIGAND THERAPY ALTERNATED WITH RADIUM-223 IN PATIENTS WITH BONE-METASTATIC, OLIGO-METASTATIC HORMONE-SENSITIVE PROSTATE CANCER AFTER CURATIVE THERAPY. (2024-518985-29-02)
    P1/2, N=6, Completed, Amsterdam UMC Stichting | Active, not recruiting --> Completed
    Trial completion
    |
    FOLH1 expression
    |
    Xofigo (radium Ra-223 dichloride)
    3ms
    Radium-223 in Biochemically Recurrent Prostate Cancer (clinicaltrials.gov)
    P2, N=19, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2027 --> Jul 2026 | Trial primary completion date: Nov 2026 --> Feb 2026
    Trial completion date • Trial primary completion date
    |
    Xofigo (radium Ra-223 dichloride)
    4ms
    IRST185.04: Randomized, multicentre phase II trial of the sequencing of Radium-223 and Docetaxel plus prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC) (2024-511660-89-00)
    P1/2, N=70, Active, not recruiting, Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    docetaxel • prednisone • Xofigo (radium Ra-223 dichloride)
    4ms
    COMRADE: Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis (clinicaltrials.gov)
    P1/2, N=145, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2026 --> Feb 2027 | Trial primary completion date: Apr 2026 --> Mar 2025
    Trial completion date • Trial primary completion date • Tumor mutational burden
    |
    CD4 (CD4 Molecule)
    |
    Lynparza (olaparib) • Xofigo (radium Ra-223 dichloride)
    4ms
    BAT-RAD: Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P2, N=47, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Feb 2027 --> Feb 2029 | Trial primary completion date: Feb 2026 --> Feb 2028
    Trial completion date • Trial primary completion date
    |
    abiraterone acetate • Xofigo (radium Ra-223 dichloride)